Moderna says FDA submission for its COVID-19 booster shot is com

Moderna says FDA submission for its COVID-19 booster shot is complete

Sep 03, 2021 2:12 PM ET | Moderna, Inc. (MRNA) | Dulan Lokuwithana, SA News Editor

 

Moderna (NASDAQ:MRNA) says that the company has completed the submission to the FDA seeking a review of its booster COVID-19 shot.

On Wednesday, Cambridge, Massachusetts-based biotech announced that it initiated the submission of its COVID-19 booster vaccine data to the FDA. 

“We are pleased to announce that today we completed our submission to the @US_FDA, which we began on Wednesday, for the evaluation of a booster dose of the Moderna COVID-19 vaccine,” Moderna (MRNA) wrote in a tweet.

The announcement by the leading COVID-19 vaccine maker comes amid concerns that U.S. is planning to move ahead with its COVID-19 booster rollout without the Moderna (MRNA) vaccine due to insufficient data submitted by the company to the FDA.

Highlighting the concerns, top health officials in the U.S. have urged the White House to scale back plans for wider distribution of COVID-19 booster shots scheduled for later this month.